EURURO Vol. 72 No. 6

e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 6 , D e c emb e r 2 0 1 7

942

The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report

E.A. Klein, A. Chait, J.M. Hafron, K.M. Kernen, K. Manickam, A.J. Stephenson, M. Wagner,

H. Zhu, A. Kestranek, B. Zaslavsky, M. Stovsky

The structure-based IsoPSA assay outperformed concentration-based

prostate-specific antigen measurement, and provided a net benefit against

other protocols. Clinical use of IsoPSA could significantly reduce unnecessary

biopsies while identifying patients needing treatment.

950

New Prostate Cancer Biomarkers: The Search Continues

D.N. Patel, S.J. Freedland

952

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets

E.J. Pietzak, A. Bagrodia, E.K. Cha, E.N. Drill, G. Iyer, S. Isharwal, I. Ostrovnaya, P. Baez,

Q. Li, M.F. Berger, A. Zehir, N. Schultz, J.E. Rosenberg, D.F. Bajorin, G. Dalbagni, H. Al-Ahmadie,

D.B. Solit, B.H. Bochner

High-grade nonmuscle invasive bladder cancer has high rates of DNA damage

repair gene alterations, mutational burden, and actionable alterations, making trials

of novel targeted agents and immunotherapies warranted.

ARID1A

mutations

are associated with recurrence after bacillus Calmette-Guérin therapy and may be

a predictive biomarker and a potential therapeutic target.

960

Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?

C.A. Rentsch, D.C. Müller, C. Ruiz, L. Bubendorf

962

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

B. Escudier, P. Sharma, D.F. McDermott, S. George, H.J. Hammers, S. Srinivas, S.S. Tykodi,

J.A. Sosman, G. Procopio, E.R. Plimack, D. Castellano, H. Gurney, F. Donskov, K. Peltola,

J. Wagstaff, T.C. Gauler, T. Ueda, H. Zhao, I.M. Waxman, R.J. Motzer, on behalf of the CheckMate

025 investigators

Consistent with the benefit demonstrated in previously treated patients

with advanced renal cell carcinoma from CheckMate 025, an overall survival

and objective response rate benefit with nivolumab versus everolimus was observed

for multiple subgroups, including prognostic risk categories, age, number and sites

of metastases, and prior therapies.

972

Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?

S.K. Pal, M.C. Maia, N. Dizman, N. Agarwal

974

Recommendations for the Management of Rare Kidney Cancers

R.H. Giles, T.K. Choueiri, D.Y. Heng, L. Albiges, J.J. Hsieh, W.M. Linehan, S. Pal, D. Maskens,

B. Paseman, E. Jonasch, G. Malouf, A.M. Molina, L. Pickering, B. Shuch, S. Srinivas, R. Srinivasan,

N.M. Tannir, A. Bex

Rare kidney cancers (ie, non–clear cell subtypes) are often treated the same way

as conventional clear-cell renal cell carcinomas, despite little evidence

from randomized trials. Molecular characterization of tumors to stratify patients

may improve outcomes. Availability of agents and trials remain a problem.

i 984

Time to Focus on the Rare—Encouraging Progress in the Management of Non–clear Cell Renal Cell Carcinoma

A. Fernando

Bladder Cancer

Kidney Cancer